JP2016048242A - 腎損傷および腎不全の診断および予後のための方法および組成物 - Google Patents
腎損傷および腎不全の診断および予後のための方法および組成物 Download PDFInfo
- Publication number
- JP2016048242A JP2016048242A JP2015208192A JP2015208192A JP2016048242A JP 2016048242 A JP2016048242 A JP 2016048242A JP 2015208192 A JP2015208192 A JP 2015208192A JP 2015208192 A JP2015208192 A JP 2015208192A JP 2016048242 A JP2016048242 A JP 2016048242A
- Authority
- JP
- Japan
- Prior art keywords
- cohort
- subject
- measured concentration
- threshold
- soluble
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 102
- 206010061481 Renal injury Diseases 0.000 title claims abstract description 45
- 238000003745 diagnosis Methods 0.000 title claims abstract description 31
- 238000004393 prognosis Methods 0.000 title claims abstract description 6
- 239000000203 mixture Substances 0.000 title abstract description 6
- 208000001647 Renal Insufficiency Diseases 0.000 title description 3
- 201000006370 kidney failure Diseases 0.000 title description 3
- 238000003556 assay Methods 0.000 claims abstract description 87
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims abstract description 37
- 101710165471 Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims abstract description 37
- 108060006698 EGF receptor Proteins 0.000 claims abstract description 31
- 102000003952 Caspase 3 Human genes 0.000 claims abstract description 30
- 108090000397 Caspase 3 Proteins 0.000 claims abstract description 30
- 102000001301 EGF receptor Human genes 0.000 claims abstract description 30
- 108010028275 Leukocyte Elastase Proteins 0.000 claims abstract description 30
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims abstract description 30
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims abstract description 30
- 229940024142 alpha 1-antitrypsin Drugs 0.000 claims abstract description 30
- 108010039471 Fas Ligand Protein Proteins 0.000 claims abstract description 28
- 101710137351 CCN family member 3 Proteins 0.000 claims abstract description 25
- 102100037872 Intercellular adhesion molecule 2 Human genes 0.000 claims abstract description 24
- 101710148794 Intercellular adhesion molecule 2 Proteins 0.000 claims abstract description 24
- 102100034388 Netrin-4 Human genes 0.000 claims abstract description 24
- 101710121532 Netrin-4 Proteins 0.000 claims abstract description 24
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 claims abstract description 22
- 238000012544 monitoring process Methods 0.000 claims abstract description 21
- 102000014702 Haptoglobin Human genes 0.000 claims abstract description 18
- 108050005077 Haptoglobin Proteins 0.000 claims abstract description 18
- 102100031170 CCN family member 3 Human genes 0.000 claims abstract description 11
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims abstract description 9
- 101710204736 Platelet endothelial cell adhesion molecule Proteins 0.000 claims abstract description 9
- 102000005623 HSP27 Heat-Shock Proteins Human genes 0.000 claims abstract 2
- 102000016799 Leukocyte elastase Human genes 0.000 claims abstract 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims abstract 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 388
- 229940109239 creatinine Drugs 0.000 claims description 194
- 210000002966 serum Anatomy 0.000 claims description 177
- 201000011040 acute kidney failure Diseases 0.000 claims description 104
- 230000003907 kidney function Effects 0.000 claims description 88
- 208000033626 Renal failure acute Diseases 0.000 claims description 66
- 239000003550 marker Substances 0.000 claims description 63
- 210000003734 kidney Anatomy 0.000 claims description 44
- 208000037806 kidney injury Diseases 0.000 claims description 38
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 36
- 230000001965 increasing effect Effects 0.000 claims description 31
- 208000012998 acute renal failure Diseases 0.000 claims description 30
- 230000003247 decreasing effect Effects 0.000 claims description 21
- 230000006872 improvement Effects 0.000 claims description 17
- 239000002872 contrast media Substances 0.000 claims description 16
- 230000024924 glomerular filtration Effects 0.000 claims description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 12
- 210000001124 body fluid Anatomy 0.000 claims description 12
- 239000010839 body fluid Substances 0.000 claims description 12
- 206010019280 Heart failures Diseases 0.000 claims description 8
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 6
- 206010040047 Sepsis Diseases 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 5
- 108010036949 Cyclosporine Proteins 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 5
- 229940126575 aminoglycoside Drugs 0.000 claims description 5
- 229960001265 ciclosporin Drugs 0.000 claims description 5
- 208000029078 coronary artery disease Diseases 0.000 claims description 5
- 229930182912 cyclosporin Natural products 0.000 claims description 5
- 230000008085 renal dysfunction Effects 0.000 claims description 5
- 102000001554 Hemoglobins Human genes 0.000 claims description 4
- 108010054147 Hemoglobins Proteins 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- 108010062374 Myoglobin Proteins 0.000 claims description 4
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 claims description 4
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 4
- 238000007675 cardiac surgery Methods 0.000 claims description 4
- 208000002296 eclampsia Diseases 0.000 claims description 4
- 229940093476 ethylene glycol Drugs 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 229960005102 foscarnet Drugs 0.000 claims description 4
- 229910001385 heavy metal Inorganic materials 0.000 claims description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 4
- 229960001101 ifosfamide Drugs 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
- 201000011461 pre-eclampsia Diseases 0.000 claims description 4
- 201000001474 proteinuria Diseases 0.000 claims description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 4
- 229960001052 streptozocin Drugs 0.000 claims description 4
- 229960001967 tacrolimus Drugs 0.000 claims description 4
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 2
- 230000007882 cirrhosis Effects 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 2
- 210000004351 coronary vessel Anatomy 0.000 claims description 2
- 238000007631 vascular surgery Methods 0.000 claims description 2
- 102000036675 Myoglobin Human genes 0.000 claims 1
- 230000009760 functional impairment Effects 0.000 claims 1
- 108010035766 P-Selectin Proteins 0.000 abstract description 21
- 102000008212 P-Selectin Human genes 0.000 abstract 1
- 239000000104 diagnostic biomarker Substances 0.000 abstract 1
- 239000000092 prognostic biomarker Substances 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
- 210000002700 urine Anatomy 0.000 description 171
- 238000005259 measurement Methods 0.000 description 80
- 230000006378 damage Effects 0.000 description 64
- 108090000765 processed proteins & peptides Proteins 0.000 description 42
- 229920001184 polypeptide Polymers 0.000 description 41
- 102000004196 processed proteins & peptides Human genes 0.000 description 41
- 239000000523 sample Substances 0.000 description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 37
- 201000010099 disease Diseases 0.000 description 36
- 201000003068 rheumatic fever Diseases 0.000 description 30
- 238000003018 immunoassay Methods 0.000 description 29
- 102100033174 Neutrophil elastase Human genes 0.000 description 28
- 210000002381 plasma Anatomy 0.000 description 28
- 102000012042 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 26
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 239000000090 biomarker Substances 0.000 description 25
- 230000035945 sensitivity Effects 0.000 description 23
- 230000001154 acute effect Effects 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- 102100039165 Heat shock protein beta-1 Human genes 0.000 description 20
- 102100023472 P-selectin Human genes 0.000 description 20
- 239000012491 analyte Substances 0.000 description 20
- 238000012360 testing method Methods 0.000 description 19
- 230000002596 correlated effect Effects 0.000 description 18
- 238000000502 dialysis Methods 0.000 description 16
- 239000012472 biological sample Substances 0.000 description 15
- 230000007423 decrease Effects 0.000 description 15
- 239000002243 precursor Substances 0.000 description 15
- 210000002889 endothelial cell Anatomy 0.000 description 14
- 208000014674 injury Diseases 0.000 description 14
- 238000011282 treatment Methods 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 12
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 208000020832 chronic kidney disease Diseases 0.000 description 11
- 238000012959 renal replacement therapy Methods 0.000 description 11
- 108010076504 Protein Sorting Signals Proteins 0.000 description 10
- 206010062237 Renal impairment Diseases 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 208000017169 kidney disease Diseases 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 238000002054 transplantation Methods 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 231100000857 poor renal function Toxicity 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 108010052285 Membrane Proteins Proteins 0.000 description 8
- 208000015698 cervical squamous intraepithelial neoplasia Diseases 0.000 description 8
- 230000034994 death Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 239000007790 solid phase Substances 0.000 description 8
- 239000004971 Cross linker Substances 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 102000018697 Membrane Proteins Human genes 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 210000000805 cytoplasm Anatomy 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 230000002250 progressing effect Effects 0.000 description 7
- 230000017854 proteolysis Effects 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 238000013517 stratification Methods 0.000 description 7
- 230000002485 urinary effect Effects 0.000 description 7
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 230000007717 exclusion Effects 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 201000000523 end stage renal failure Diseases 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- -1 0.3 mg / dL or 25% Chemical compound 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 102100024646 Cell adhesion molecule 2 Human genes 0.000 description 4
- 101710197434 Cell adhesion molecule 2 Proteins 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 102000013519 Lipocalin-2 Human genes 0.000 description 4
- 108010051335 Lipocalin-2 Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000028208 end stage renal disease Diseases 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 210000005239 tubule Anatomy 0.000 description 4
- 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 3
- 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 3
- 102000012192 Cystatin C Human genes 0.000 description 3
- 108010061642 Cystatin C Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 102100030856 Myoglobin Human genes 0.000 description 3
- 206010047139 Vasoconstriction Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 238000003066 decision tree Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 229940089988 hep-lock Drugs 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 230000036571 hydration Effects 0.000 description 3
- 238000006703 hydration reaction Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 230000025033 vasoconstriction Effects 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 150000003923 2,5-pyrrolediones Chemical class 0.000 description 2
- QZDDFQLIQRYMBV-UHFFFAOYSA-N 2-[3-nitro-2-(2-nitrophenyl)-4-oxochromen-8-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(C=2[N+]([O-])=O)=O)=C1OC=2C1=CC=CC=C1[N+]([O-])=O QZDDFQLIQRYMBV-UHFFFAOYSA-N 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 2
- 101710145634 Antigen 1 Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 2
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 2
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102100037738 Fatty acid-binding protein, heart Human genes 0.000 description 2
- 206010018366 Glomerulonephritis acute Diseases 0.000 description 2
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102100025392 Isovaleryl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 102100036836 Natriuretic peptides B Human genes 0.000 description 2
- 101710187802 Natriuretic peptides B Proteins 0.000 description 2
- 208000000770 Non-ST Elevated Myocardial Infarction Diseases 0.000 description 2
- 206010030302 Oliguria Diseases 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- 208000023146 Pre-existing disease Diseases 0.000 description 2
- 108090000783 Renin Proteins 0.000 description 2
- 102100028255 Renin Human genes 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 102000014456 Trefoil Factor-3 Human genes 0.000 description 2
- 108010078184 Trefoil Factor-3 Proteins 0.000 description 2
- 206010048302 Tubulointerstitial nephritis Diseases 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000001801 Z-test Methods 0.000 description 2
- 231100000851 acute glomerulonephritis Toxicity 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000013528 artificial neural network Methods 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 230000002612 cardiopulmonary effect Effects 0.000 description 2
- 238000013130 cardiovascular surgery Methods 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000002542 deteriorative effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000001434 glomerular Effects 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
- 201000006334 interstitial nephritis Diseases 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- WFLQAMUOBIONDG-UHFFFAOYSA-N phenoxyarsonic acid Chemical compound O[As](O)(=O)OC1=CC=CC=C1 WFLQAMUOBIONDG-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 108010008064 pro-brain natriuretic peptide (1-76) Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000002601 radiography Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 108010055851 Acetylglucosaminidase Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 102000011690 Adiponectin Human genes 0.000 description 1
- 108010076365 Adiponectin Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102100022463 Alpha-1-acid glycoprotein 1 Human genes 0.000 description 1
- 101710186701 Alpha-1-acid glycoprotein 1 Proteins 0.000 description 1
- 102100022749 Aminopeptidase N Human genes 0.000 description 1
- 102100034613 Annexin A2 Human genes 0.000 description 1
- 108090000668 Annexin A2 Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 description 1
- 102100023703 C-C motif chemokine 15 Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 101710098272 C-X-C motif chemokine 11 Proteins 0.000 description 1
- 102100031171 CCN family member 1 Human genes 0.000 description 1
- 108010049990 CD13 Antigens Proteins 0.000 description 1
- 108010028310 Calbindin 1 Proteins 0.000 description 1
- 102000016838 Calbindin 1 Human genes 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 102000052052 Casein Kinase II Human genes 0.000 description 1
- 108010010919 Casein Kinase II Proteins 0.000 description 1
- 102000004225 Cathepsin B Human genes 0.000 description 1
- 108090000712 Cathepsin B Proteins 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108010055165 Chemokine CCL4 Proteins 0.000 description 1
- 102000001326 Chemokine CCL4 Human genes 0.000 description 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 102000003780 Clusterin Human genes 0.000 description 1
- 108090000197 Clusterin Proteins 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010019961 Cysteine-Rich Protein 61 Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102100034274 Diamine acetyltransferase 1 Human genes 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 102100038002 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit STT3A Human genes 0.000 description 1
- 101710133440 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit STT3A Proteins 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 101800004490 Endothelin-1 Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 101710136552 Fatty acid-binding protein, heart Proteins 0.000 description 1
- 102100026745 Fatty acid-binding protein, liver Human genes 0.000 description 1
- 101710188974 Fatty acid-binding protein, liver Proteins 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- 102000027487 Fructose-Bisphosphatase Human genes 0.000 description 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 1
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
- 102000013382 Gelatinases Human genes 0.000 description 1
- 108010026132 Gelatinases Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 108010073791 Glycine amidinotransferase Proteins 0.000 description 1
- 102100040870 Glycine amidinotransferase, mitochondrial Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102100034221 Growth-regulated alpha protein Human genes 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 1
- 102400000142 Haptoglobin alpha chain Human genes 0.000 description 1
- 101800000803 Haptoglobin alpha chain Proteins 0.000 description 1
- 102400000143 Haptoglobin beta chain Human genes 0.000 description 1
- 101800001341 Haptoglobin beta chain Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 1
- 101000641077 Homo sapiens Diamine acetyltransferase 1 Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101001027663 Homo sapiens Fatty acid-binding protein, heart Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000999377 Homo sapiens Interferon-related developmental regulator 1 Proteins 0.000 description 1
- 101000881168 Homo sapiens SPARC Proteins 0.000 description 1
- 101000801228 Homo sapiens Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 description 1
- 101000801232 Homo sapiens Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000004372 Insulin-like growth factor binding protein 2 Human genes 0.000 description 1
- 108090000964 Insulin-like growth factor binding protein 2 Proteins 0.000 description 1
- 102000004375 Insulin-like growth factor-binding protein 1 Human genes 0.000 description 1
- 108090000957 Insulin-like growth factor-binding protein 1 Proteins 0.000 description 1
- 102000004883 Insulin-like growth factor-binding protein 6 Human genes 0.000 description 1
- 108090001014 Insulin-like growth factor-binding protein 6 Proteins 0.000 description 1
- 102100036527 Interferon-related developmental regulator 1 Human genes 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102400000531 Interleukin-16 Human genes 0.000 description 1
- 101800003050 Interleukin-16 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000037862 Ion Transporter Human genes 0.000 description 1
- 108091006671 Ion Transporter Proteins 0.000 description 1
- 108010013792 Isovaleryl-CoA Dehydrogenase Proteins 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 108010004098 Leucyl aminopeptidase Proteins 0.000 description 1
- 102000002704 Leucyl aminopeptidase Human genes 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- 102100026261 Metalloproteinase inhibitor 3 Human genes 0.000 description 1
- 102100030335 Midkine Human genes 0.000 description 1
- 108010092801 Midkine Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 101000605526 Mus musculus Kallikrein-1 Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 102000003729 Neprilysin Human genes 0.000 description 1
- 108090000028 Neprilysin Proteins 0.000 description 1
- 102000009065 Netrin-1 Human genes 0.000 description 1
- 108010074223 Netrin-1 Proteins 0.000 description 1
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 description 1
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 102000008108 Osteoprotegerin Human genes 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 102100035591 POU domain, class 2, transcription factor 2 Human genes 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101000621511 Potato virus M (strain German) RNA silencing suppressor Proteins 0.000 description 1
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100030122 Protein O-GlcNAcase Human genes 0.000 description 1
- 102100032421 Protein S100-A6 Human genes 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 101000999374 Rattus norvegicus Interferon-related developmental regulator 1 Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108010005260 S100 Calcium Binding Protein A6 Proteins 0.000 description 1
- 108091006735 SLC22A2 Proteins 0.000 description 1
- 108091006649 SLC9A3 Proteins 0.000 description 1
- 102100037599 SPARC Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 102100030375 Sodium/hydrogen exchanger 3 Human genes 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 102100033470 Tubulointerstitial nephritis antigen Human genes 0.000 description 1
- 101710185398 Tubulointerstitial nephritis antigen Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102400000084 Tumor necrosis factor ligand superfamily member 6, soluble form Human genes 0.000 description 1
- 101800000859 Tumor necrosis factor ligand superfamily member 6, soluble form Proteins 0.000 description 1
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 description 1
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 description 1
- 102000018614 Uromodulin Human genes 0.000 description 1
- 108010027007 Uromodulin Proteins 0.000 description 1
- 101000998548 Yersinia ruckeri Alkaline proteinase inhibitor Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 description 1
- 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004082 amperometric method Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000013398 bayesian method Methods 0.000 description 1
- 238000013531 bayesian neural network Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000007413 cholesterol embolism Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012043 cost effectiveness analysis Methods 0.000 description 1
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical class NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000572 ellipsometry Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000005086 glomerual capillary Anatomy 0.000 description 1
- 150000002337 glycosamines Chemical group 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 150000002463 imidates Chemical class 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000005305 interferometry Methods 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- 229940118526 interleukin-9 Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 239000000193 iodinated contrast media Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000003589 nefrotoxic effect Effects 0.000 description 1
- 231100000381 nephrotoxic Toxicity 0.000 description 1
- HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 108091000053 retinol binding Proteins 0.000 description 1
- 102000029752 retinol binding Human genes 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 229960002101 secretin Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 210000004926 tubular epithelial cell Anatomy 0.000 description 1
- 230000010024 tubular injury Effects 0.000 description 1
- 208000037978 tubular injury Diseases 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000011547 urine creatinine measurement Methods 0.000 description 1
- 102000009816 urokinase plasminogen activator receptor activity proteins Human genes 0.000 description 1
- 108040001269 urokinase plasminogen activator receptor activity proteins Proteins 0.000 description 1
- 230000006496 vascular abnormality Effects 0.000 description 1
- 230000009723 vascular congestion Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
Abstract
Description
号、2008年8月29日に出願された同第61/093,247号、2008年8月29日に出願された同第61/093,249号、2008年8月29日に出願された同第61/093,262号、2008年8月29日に出願された同第61/093,263号、2008年8月29日に出願された同第61/093,264号、2008年8月29日に出願された同第61/093,266号、2008年8月29日に出願された同第61/093,244号、および、2008年8月29日に出願された同第61/093,272号の優先権を主張するものであり、これら各々の全ての表、図面および特許請求の範囲を含む内容全体は本明細書に組み込まれる。
本発明の背景の以下の論議は、読者が本発明を理解するのを助けるためだけに提供されており、本発明に対する先行技術を説明または構成すると認められるものではない。
「危険」:血清クレアチニンがベースラインから1.5倍増加した、または、6時間の尿産生が<0.5mL/kg体重/時である;
「損傷」:血清クレアチニンがベースラインから2.0倍増加した、または、12時間の尿産生が<0.5mL/kg/時である;
「不全」:血清クレアチニンがベースラインから3.0倍増加した、または、クレアチニン>355μmol/L(44を超える上昇とともに)、もしくは24時間の尿量が0.3mL/kg/時未満、もしくは少なくとも12時間の無尿;
かつ、2つの臨床転帰が含まれる:
「損失」:4週間を超える腎置換療法の持続的必要性あり。
「ESRD」:末期腎疾患―3ヶ月間を超える透析の必要性あり。
これらの判断基準は、RIFLE判断基準と呼ばれ、腎状態を分類するための有用な臨床ツールを提供するものである。Kellumによるクリティカル・ケア・メディスン(Crit. Care Med.)36:S141〜45、2008年、および、Ricciらによる、キドニー・インターナショナル(Kidney Int.)73、538〜546、2008年(これら各々の内容全体が参照により本明細書に組み込まれる)で論議されたように、RIFLE判断基準は、多数の研究で検証されているAKIの一様な定義を提供する。
「ステージI」:血清クレアチニンの0.3mg/dL以上の増加(≧26.4μmol/L)、もしくはベースラインから150%(1.5倍)以上への増加、または、6時間を超える間の尿量が1時間当たり0.5mL/kg未満である;
「ステージII」:血清クレアチニンのベースラインから200%を超える(>2倍)増加、または、12時間を超える間の尿量が1時間当たり0.5mL/kg未満
「ステージIII」血清クレアチニンのベースラインから300%を超える(>3倍)増加、または、少なくとも44μmol/Lの急性増加を伴う血清クレアチニン≧354μmol/L、または、24時間の尿量が1時間当たり0.3mL/kg未満であるか、もしくは、12時間の無尿。
1を超えるオッズ比、好ましくは少なくとも約2以上または約0.5以下、より好ましくは少なくとも約3以上または約0.33以下、依然としてより好ましくは少なくとも約4以上または約0.25以下、さらにより好ましくは少なくとも約5以上または約0.2以下、そして最も好ましくは少なくとも約10以上または約0.1以下のオッズ比:
0.2を超える対応する感受性、好ましくは約0.3を超える、より好ましくは約0.4を超える、依然としてより好ましくは少なくとも約0.5、さらにより好ましくは約0.6、さらにより好ましくは約0.7を超える、依然としてより好ましくは約0.8を超える、より好ましくは約0.9を超える、そして最も好ましくは約0.95を超える対応する感受性を有する、0.5を超える特異性、好ましくは少なくとも約0.6、より好ましくは少なくとも約0.7、依然としてより好ましくは少なくとも約0.8、さらにより好ましくは少なくとも約0.9、そして最も好ましくは少なくとも約0.95である特異性;
0.2を超える対応する特異性、好ましくは約0.3を超える、より好ましくは約0.4を超える、依然としてより好ましくは少なくとも約0.5、さらにより好ましくは約0.6、さらにより好ましくは約0.7を超える、依然としてより好ましくは約0.8を超える、より好ましくは約0.9を超える、そして最も好ましくは約0.95を超える対応する特異性を有する、0.5を超える感受性、好ましくは少なくとも約0.6、より好ましくは少なくとも約0.7、依然としてより好ましくは少なくとも約0.8、さらにより好ましくは少なくとも約0.9、そして最も好ましくは少なくとも約0.95の感受性;
少なくとも約75%の特異性と組み合わせた、少なくとも約75%の感受性;
1を超える陽性尤度比(感受性/(1−特異性)として計算される)、少なくとも約2、より好ましくは少なくとも約3、依然としてより好ましくは少なくとも約5、そして最も好ましくは少なくとも約10の陽性尤度比;あるいは、
1未満の陰性尤度比((1−感受性)/特異性として計算される)、約0.5以下、より好ましくは約0.3以下、そして最も好ましくは約0.1以下の陰性尤度比。
任意の上記測定値の文脈における用語「約」は、与えられた測定値の+/−5%に言及するものである。
本発明は、1以上の腎臓損傷マーカーの測定による、腎機能の損傷、腎機能減少、および/または急性腎不全を患っている、あるいは患うリスクのある対象における、診断、鑑別診断、リスク階級化、監視、分類、および、治療計画の決定のための方法ならびに組成物に関する。様々な実施形態において、可溶性P−セレクチン、タンパク質NOVホモログ、可溶性上皮増殖因子受容体、ネトリン−4、ハプトグロビン、熱ショックタンパク質β−1、α−1−アンチトリプシン、白血球エラスターゼ、可溶性腫瘍壊死因子受容体スーパーファミリーメンバー6、可溶性腫瘍壊死因子リガンドスーパーファミリーメンバー6、可溶性細胞間接着分子2、カスパーゼ−3(および、最も好ましくは活性型カスパーゼ−3)、および、可溶性血小板内皮細胞接着分子からなる群から選択される1以上のマーカー、あるいは、それに関連する1以上のマーカーの測定された濃度は、対象の腎状態に相関される。
本明細書で使用されるように、「腎機能の損傷」は、腎機能の測定における急激な(14日以内、好ましくは7日以内、より好ましくは72時間以内、そして依然としてより好ましくは48時間以内)測定可能な減少である。そのような損傷は、例えば、糸球体濾過率または推定GFRの低下、尿量の減少、血清クレアチニンの増加、血清シスタチンCの増加、腎置換療法の必要性などによって特定され得る。「腎機能における改善」は、腎機能の測定における急激な(14日以内、好ましくは7日以内、より好ましくは72時間以内、そして依然としてより好ましくは48時間以内)測定可能な増加である。GFRを測定および/または推定するための好ましい方法は、本明細書において以下で説明される。
本明細書において使用されるように、「腎機能減少」は、血清クレアチニンにおける0.1mg/dL以上(≧8.8μmol/L)の絶対的増加、血清クレアチニンにおける20%(ベースラインから1.2倍)以上のパーセンテージ増加、あるいは、尿量の減少(1時間当たり0.5mL/kg未満と記述される乏尿)によって特定される腎臓機能における、急激な(14日以内、好ましくは7日以内、より好ましくは72時間以内、そして依然としてより好ましくは48時間以内)減少である。
本明細書において使用されるように、「急性腎不全」または「ARF」は、血清クレアチニンにおける0.3mg/dL以上(≧26.4μmol/L)の絶対的増加、血清クレアチニンにおける50%(ベースラインから1.5倍)以上のパーセンテージ増加、または、尿量の減少(少なくとも6時間における1時間当たり0.5mL/kg未満と記述される乏尿)によって特定される腎臓機能における、急激な(14日以内、好ましくは7日以内、より好ましくは72時間以内、そして依然としてより好ましくは48時間以内)減少である。この用語は、「急性腎臓損傷」または「AKI」と同義である。
残基 長さ ドメインID
1-41 41 シグナル配列
42-830 789 p−セレクチン
42-771 730 細胞外
772-795 24 膜貫通
796-830 35 細胞質
残基 長さ ドメインID
1-31 31 シグナル配列
32-357 326 タンパク質NOVホモログ
残基 長さ ドメインID
1-24 24 シグナル配列
25-1210 1186 上皮増殖因子受容体
25-645 621 細胞外
646-668 23 膜貫通
669-1210 542 細胞質
残基 長さ ドメインID
1-18 18 開始メチオニン
19-628 610 ネトリン−4
残基 長さ ドメインID
1-18 18 シグナル配列
19-406 388 ハプトグロビン
19-160 142 ハプトグロビンα鎖
162-406 245 ハプトグロビンβ鎖
残基 長さ ドメインID
1-24 24 シグナル配列
25-418 394 α−1−アンチトリプシン
残基 長さ ドメインID
1-27 315 シグナル配列
28-29 2 プロペプチド
30-267 238 白血球エラスターゼ
残基 長さ ドメインID
1-25 25 シグナル配列
26-335 310 腫瘍壊死因子受容体スーパーファミリーメンバー6
26-173 148 細胞外
174-190 17 膜貫通
191-335 145 細胞質
残基 長さ ドメインID
1-281 281 腫瘍壊死因子リガンドスーパーファミリーメンバー6、膜結合型
130-281 152 腫瘍壊死因子リガンドスーパーファミリーメンバー6、可溶形態
1-180 180 細胞質
81-102 22 膜アンカー信号
103-281 179 細胞外
残基 長さ ドメインID
1-21 21 シグナル配列
22-275 254 細胞間接着分子2
22-223 202 細胞外
224-248 25 膜貫通
249-275 27 細胞質
残基 長さ ドメインID
1-9 9 プロペプチド
10-28 19 プロペプチド
29-175 147 カスパーゼ−3 p17サブユニット
176-277 102 カスパーゼ−3 p12サブユニット
残基 長さ ドメインID
1-27 27 シグナル配列
28-738 711 血小板内皮細胞接着分子
28-601 574 細胞外
602-620 19 膜貫通
621-738 118 細胞質
残基 長さ ドメインID
1-24 24 シグナル配列
25-1210 1186 上皮増殖因子受容体
25-645 621 細胞外
646-668 23 膜貫通
669-1210 542 細胞質
アッセイ相関
<35mL/時(危険)、<21mL/時(損傷)、または、<4mL/時(不全)
包含基準
18歳以上の男女;
造影剤の血管内投与を伴うX線撮影/血管造影手技(CTスキャンまたは冠動脈インターベンションなど)を受けている;
造影剤投与後少なくとも48時間入院が予想される。
研究参加のための書面によるインフォームドコンセントを提供すること、および全ての研究手順に従うことができ、それらに前向きであること。
除外基準
腎移植レシピエント;
造影剤手技前で腎機能が急性的に悪化している;
すでに透析を受けている(急性または慢性のいずれも)、あるいは、登録時に透析の切迫した必要性がある;
(心肺バイパス術を伴うなどの)大きな外科手術、あるいは、造影剤投与後48時間以内にさらなる腎傷害の重大なリスクを伴う造影剤による追加的撮像手技を、受けると予想される;
30日前以内の実験療法を含むインターベンショナル臨床研究への参加;
ヒト免疫不全ウイルス(HIV)または肝炎ウイルスによる感染が分かっている。
包含基準
18歳以上の男女;
心臓血管手術を受けている;
腎置換リスク評点のためのトロント/オタワ予測リスク指標が少なくとも2である(Wijeysunderaらによる、JAMA 297:1801〜9、2007年)、ならびに、
研究参加のための書面によるインフォームドコンセントを提供すること、および全ての研究手順に従うことができ、それらに前向きであること。
除外基準
妊娠が分かっている;
腎移植の前歴;
登録前に腎機能が急性的に悪化している(例えばRIFLE判断基準の任意のカテゴリー);
すでに透析を受けている(急性または慢性のいずれも)、あるいは、登録時に透析の切迫した必要性がある;
現在、別の臨床研究に登録されている、あるいは、薬物注入またはAKIのための治療的介入を含む心臓手術の7日以内に別の臨床研究に登録されると予想されている;
ヒト免疫不全ウイルス(HIV)または肝炎ウイルスによる感染が分かっている。
包含基準
18歳以上の男女;
研究集団1:ショック(SBP<90mmHg、および/または、MAP>60mmHgを維持するために血管収縮支持が必要、および/または、少なくとも40mmHgのSBPにおける実証された降下);ならびに、
敗血症、
のうちの少なくとも1つを有するほぼ300人の患者;
研究集団2:IV抗生物質が登録の24時間以内にコンピュータ化された医師受注(CPOE)に注文された;
登録の24時間以内での造影剤曝露;
急性非代償性心不全による腹腔内圧の増加;ならびに、
ICU入院の主な理由としての、および登録後48時間ICU内に入院させられる可能性がある、重篤な外傷;
のうちの少なくとも1つを有するほぼ300人の患者;
研究集団3:急性腎損傷についての既知のリスク因子により急性医療環境(ICUまたはED)を通した入院が予想される(例えば、敗血症、低血圧/ショック(ショック=収縮期BP<90mmHg、および/または、MAP>60mmHgを維持するために血管収縮支持が必要、および/または、SBP>40mmHgの実証された降下)、大きな外傷、出血、または大手術);
ならびに/あるいは、登録後少なくとも24時間ICUへの入院が予想される、
ほぼ300人の患者。
除外基準
妊娠が分かっている;
施設に収容された個人;
腎移植の前歴;
登録前に腎機能が急性的に悪化していると分かっている(例えばRIFLE判断基準の任意のカテゴリー);
登録5日前以内に透析を受けた(急性または慢性のいずれも)、あるいは登録時に透析の切迫した必要性がある;
ヒト免疫不全ウイルス(HIV)または肝炎ウイルスによる感染が分かっている;
上記で明記された包含基準SBP<90mmHgのみを満たす、かつ、参加している医師または主任調査官の意見においてショックを有しない。
可溶性P−セレクチン:
可溶性P−セレクチン:
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
可溶性P−セレクチン:
可溶性腫瘍壊死因子リガンドスーパーファミリーメンバー6:
可溶性P−セレクチン:
可溶性P−セレクチン:
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
可溶性P−セレクチン:
α−1−アンチトリプシン:
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
α−1−アンチトリプシン:
可溶性P−セレクチン:
可溶性P−セレクチン:
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
可溶性P−セレクチン:
可溶性P−セレクチン:
可溶性P−セレクチン:
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
可溶性P−セレクチン:
α−1−アンチトリプシン:
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
血清クレアチニン測定値または尿量で判定したコホート1対コホート2
α−1−アンチトリプシン:
Claims (11)
- 対象における将来的な急性腎不全(ARF)を評価するための方法であって、
1以上のアッセイ結果を提供するために前記対象から得られた体液サンプルに対して可溶性腫瘍壊死因子受容体スーパーファミリーメンバー6を含む1以上の腎臓損傷マーカーを検出するよう構成された1以上のアッセイを実施することと、
前記1以上のアッセイ結果を前記対象の将来的なARFと相関させることを含み、
前記相関ステップは、前記アッセイで得られた測定濃度を、閾値濃度と比較することによって、前記対象の将来的なARFの見込みを決定することを含み、ここで前記将来的なARFは、前記対象から体液サンプルを得た時点から72時間以内に起こるARFである、方法。 - 前記アッセイ結果は、可溶性腫瘍壊死因子受容体スーパーファミリーメンバー6の測定された濃度を含む、請求項1に記載の方法。
- 前記アッセイ結果は、さらに、
(i)タンパク質NOVホモログの測定された濃度、
(ii)可溶性上皮増殖因子受容体の測定された濃度、
(iii)ネトリン−4の測定された濃度、
(iv)ハプトグロビンの測定された濃度、
(v)α−1−アンチトリプシンの測定された濃度、
(vi)白血球エラスターゼの測定された濃度、
(vii)可溶性腫瘍壊死因子リガンドスーパーファミリーメンバー6の測定された濃度、
(viii)熱ショックタンパク質β−1の測定された濃度、
(ix)可溶性細胞間接着分子2の測定された濃度、
(x)活性型カスパーゼ−3の測定された濃度、および、
(xi)可溶性血小板内皮細胞接着分子の測定された濃度、
のうちの1以上を含む、請求項2に記載の方法。 - 前記相関ステップは、前記アッセイ結果に基づき、前記対象の将来的なARFのリスク階級化、診断、段階分け、予後、分類、および監視のうちの1以上を決定することを含む、請求項2または3に記載の方法。
- 前記相関ステップは、各アッセイ結果に対して、前記測定濃度を閾値濃度と比較すること、ならびに、
AUC>0.5である陽性進行マーカーについて、前記測定された濃度が前記閾値を上回る場合に将来的なARFを患う見込み増加を前記対象に割り当てること、または、前記測定された濃度が前記閾値未満である場合に将来的なARFを患う見込み減少を前記対象に割り当てること、あるいは、
AUC<0.5である陰性進行マーカーについて、前記測定された濃度が前記閾値未満である場合に将来的なARFを患う見込み増加を前記対象に割り当てること、または、前記測定された濃度が前記閾値を上回る場合に将来的なARFを患う見込み減少を前記対象に割り当てること、
を含む、請求項1〜3の何れか一項に記載の方法。 - 前記将来的なARFは、前記対象から体液サンプルを得た時点から、48時間または24時間以内に起こる可能性がある、請求項1〜3の何れか一項に記載の方法。
- 前記対象は、腎前性、内因性腎性、または腎後性ARFについての1以上の既知リスク因子の前記対象における先在に基づく将来的なARFの評価のために選択されるか、または、
前記対象は、うっ血性心不全、子癇前症、子癇、真性糖尿病、高血圧、冠動脈疾患、蛋白尿、腎機能不全、正常範囲未満の糸球体濾過、硬変、正常範囲を上回る血清クレアチニン、敗血症、腎機能の損傷、腎機能減少、もしくはARFのうちの1以上の既存診断に基づいて、または、大きな血管手術、冠動脈バイパス術もしくは他の心臓手術を受けているか、または受けたことがあることに基づいて、または、NSAID、シクロスポリン、タクロリムス、アミノグリコシド、ホスカルネット、エチレングリコール、ヘモグロビン、ミオグロビン、イホスファミド、重金属、メトトレキサート、放射線造影剤もしくはストレプトゾトシンへの曝露に基づいて、将来的なARFの評価をするために選択される、請求項1〜3の何れか一項に記載の方法。 - 前記相関ステップは、前記アッセイ結果に基づいて、ARFの発生または不発生の診断を前記対象に割り当てることを含み、
前記アッセイ結果は、可溶性腫瘍壊死因子受容体スーパーファミリーメンバー6の測定された濃度を含み、
前記相関ステップは、各アッセイ結果に対して、前記測定濃度を閾値濃度と比較すること、ならびに、
AUC>0.5である陽性進行マーカーについて、前記測定された濃度が前記閾値を上回る場合にARFの発生を前記対象に割り当てること、または、前記測定された濃度が前記閾値未満である場合にARFの不発生を前記対象に割り当てること、あるいは、
AUC<0.5である陰性進行マーカーについて、前記測定された濃度が前記閾値未満である場合にARFの発生を前記対象に割り当てること、または、前記測定された濃度が前記閾値を上回る場合にARFの不発生を前記対象に割り当てること、
を含む、請求項1〜3の何れか一項に記載の方法。 - 前記相関ステップは、前記アッセイ結果に基づいて、ARFを患っている対象において、腎機能が改善しているか否か、または悪化しているか否かを査定することを含み、
前記アッセイ結果は、可溶性腫瘍壊死因子受容体スーパーファミリーメンバー6の測定された濃度を含み、
前記相関ステップは、各アッセイ結果について、前記測定濃度を閾値濃度と比較すること、ならびに、
AUC>0.5である陽性進行マーカーについて、前記測定された濃度が前記閾値を上回る場合に腎機能の悪化を前記対象に割り当てること、または、前記測定された濃度が前記閾値未満である場合に腎機能の改善を割り当てること、あるいは、
AUC<0.5である陰性進行マーカーについて、前記測定された濃度が前記閾値未満である場合に腎機能の悪化を前記対象に割り当てること、または、前記測定された濃度が前記閾値を上回る場合に腎機能の改善を割り当てること、
を含む、請求項1〜3の何れか一項に記載の方法。 - 前記方法は、前記対象において急性腎不全の将来的な発生または不発生のリスクを決定する方法である、請求項1〜3の何れか一項に記載の方法。
- 将来的な急性腎損傷の評価のための可溶性腫瘍壊死因子受容体スーパーファミリーメンバー6の使用であって、前記評価は、請求項1に記載の方法において対象から体液サンプルを得た時点から72時間以内に急性腎不全が起こる見込みを割り当てることを含む、使用。
Applications Claiming Priority (26)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9273308P | 2008-08-28 | 2008-08-28 | |
US61/092,733 | 2008-08-28 | ||
US9327208P | 2008-08-29 | 2008-08-29 | |
US9326308P | 2008-08-29 | 2008-08-29 | |
US9290508P | 2008-08-29 | 2008-08-29 | |
US9326608P | 2008-08-29 | 2008-08-29 | |
US9292608P | 2008-08-29 | 2008-08-29 | |
US9324408P | 2008-08-29 | 2008-08-29 | |
US9326408P | 2008-08-29 | 2008-08-29 | |
US9291208P | 2008-08-29 | 2008-08-29 | |
US9324708P | 2008-08-29 | 2008-08-29 | |
US9315408P | 2008-08-29 | 2008-08-29 | |
US9326208P | 2008-08-29 | 2008-08-29 | |
US9324908P | 2008-08-29 | 2008-08-29 | |
US61/093,266 | 2008-08-29 | ||
US61/093,262 | 2008-08-29 | ||
US61/093,263 | 2008-08-29 | ||
US61/093,249 | 2008-08-29 | ||
US61/093,247 | 2008-08-29 | ||
US61/093,272 | 2008-08-29 | ||
US61/092,912 | 2008-08-29 | ||
US61/092,905 | 2008-08-29 | ||
US61/092,926 | 2008-08-29 | ||
US61/093,264 | 2008-08-29 | ||
US61/093,154 | 2008-08-29 | ||
US61/093,244 | 2008-08-29 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011525260A Division JP2012501456A (ja) | 2008-08-28 | 2009-08-28 | 腎損傷および腎不全の診断および予後のための方法および組成物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016048242A true JP2016048242A (ja) | 2016-04-07 |
JP6126186B2 JP6126186B2 (ja) | 2017-05-10 |
Family
ID=41721965
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011525260A Pending JP2012501456A (ja) | 2008-08-28 | 2009-08-28 | 腎損傷および腎不全の診断および予後のための方法および組成物 |
JP2015208192A Expired - Fee Related JP6126186B2 (ja) | 2008-08-28 | 2015-10-22 | 腎損傷および腎不全の診断および予後のための方法および組成物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011525260A Pending JP2012501456A (ja) | 2008-08-28 | 2009-08-28 | 腎損傷および腎不全の診断および予後のための方法および組成物 |
Country Status (12)
Country | Link |
---|---|
US (2) | US11150250B2 (ja) |
EP (3) | EP2743702B1 (ja) |
JP (2) | JP2012501456A (ja) |
KR (1) | KR20110073471A (ja) |
CN (2) | CN105067819B (ja) |
AU (1) | AU2009285550B2 (ja) |
BR (1) | BRPI0917711A2 (ja) |
CA (1) | CA2735587A1 (ja) |
HK (3) | HK1153268A1 (ja) |
MX (2) | MX2011002233A (ja) |
NZ (2) | NZ610356A (ja) |
WO (1) | WO2010025424A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110221337A (zh) * | 2019-06-28 | 2019-09-10 | 南华大学 | 一种利用α-1抗蛋白酶评价铀矿粉尘内照射生物损伤的方法 |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2743702B1 (en) | 2008-08-28 | 2017-08-09 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
CN105021826A (zh) | 2008-08-29 | 2015-11-04 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
EP2347260A4 (en) * | 2008-10-21 | 2012-09-26 | Astute Medical Inc | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE |
EP3246707B1 (en) | 2008-10-21 | 2020-09-30 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
EP2913676A1 (en) | 2008-11-10 | 2015-09-02 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
NZ592552A (en) * | 2008-11-22 | 2013-12-20 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
US9229010B2 (en) | 2009-02-06 | 2016-01-05 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
EP2462440B1 (en) | 2009-08-07 | 2017-05-17 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
MX340078B (es) | 2009-11-07 | 2016-06-24 | Astute Medical Inc | Metodos y composiciones para el diagnostico y pronostico de daño renal y falla renal. |
US20120156701A1 (en) * | 2009-12-20 | 2012-06-21 | Joseph Anderberg | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
NZ600828A (en) | 2009-12-20 | 2014-09-26 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
SI2666872T1 (sl) | 2010-02-05 | 2016-08-31 | Astute Medical, Inc. | Postopki in sestavki za diagnozo in prognozo ledvične poškodbe in odpovedi ledvic |
AU2011220413B2 (en) | 2010-02-26 | 2015-07-23 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
AU2011269847A1 (en) | 2010-02-26 | 2013-01-31 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
US20130210029A1 (en) * | 2010-03-01 | 2013-08-15 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure in a non-surgical icu population |
WO2011162821A1 (en) | 2010-06-23 | 2011-12-29 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
US10557856B2 (en) * | 2010-09-24 | 2020-02-11 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Biomarkers of renal injury |
NZ609126A (en) * | 2010-09-24 | 2015-05-29 | Astute Medical Inc | Methods and compositions for the evaluation of renal injury using hyaluronic acid |
CA2824434A1 (en) * | 2011-01-08 | 2012-07-12 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
WO2013009573A1 (en) * | 2011-07-09 | 2013-01-17 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
WO2013043310A1 (en) * | 2011-08-26 | 2013-03-28 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
EP3282257A1 (en) * | 2011-11-22 | 2018-02-14 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
WO2013086359A1 (en) * | 2011-12-08 | 2013-06-13 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
WO2014113558A1 (en) | 2013-01-17 | 2014-07-24 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
US20160003850A1 (en) * | 2013-02-26 | 2016-01-07 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
WO2015084939A1 (en) | 2013-12-03 | 2015-06-11 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
US9957219B2 (en) | 2013-12-04 | 2018-05-01 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2015119899A1 (en) | 2014-02-06 | 2015-08-13 | Merck Sharp & Dohme Corp. | Antidiabetic compounds |
GB201404789D0 (en) * | 2014-03-18 | 2014-04-30 | Univ Dundee | Biomarkers |
WO2016164854A1 (en) | 2015-04-09 | 2016-10-13 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
US11243217B2 (en) | 2016-06-06 | 2022-02-08 | Astute Medical, Inc. | Management of acute kidney injury using insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 |
EP3472347B1 (en) * | 2016-06-17 | 2023-01-04 | F. Hoffmann-La Roche AG | In vitro nephrotoxicity screening assay |
EP3577458A4 (en) | 2017-02-06 | 2021-04-07 | Astute Medical, Inc. | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PREDICTION OF RENAL LESION AND RENAL INSUFFICIENCY |
WO2019075411A1 (en) * | 2017-10-12 | 2019-04-18 | Cedars-Sinai Medical Center | BIOMARKERS OF PROGNOSIS AND PROGRESSION OF CHRONIC NEPHROPATHY |
US20220178946A1 (en) * | 2018-11-02 | 2022-06-09 | Prevencio, Inc. | Prognostic and diagnostic methods for risk of acute kidney injury |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005042719A2 (en) * | 2003-10-30 | 2005-05-12 | The Cbr Institute For Biomedical Research, Inc. | Methods for treating and preventing ischemia-reperfusion injury using rna interfering agents |
JP2005534641A (ja) * | 2002-05-23 | 2005-11-17 | トラスティース・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | Fasペプチド模倣体およびその使用 |
US20070031905A1 (en) * | 2005-08-02 | 2007-02-08 | Board Of Regents, The University Of Texas System | Soluble fas urinary marker for the detection of bladder transitional cell carcinoma |
JP4339405B2 (ja) * | 1996-10-31 | 2009-10-07 | 持田製薬株式会社 | 予防・治療剤 |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1429031A1 (ru) | 1986-06-20 | 1988-10-07 | Калининский Государственный Медицинский Институт | Способ дифференциальной диагностики гломерулонефрита и пиелонефрита |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5028535A (en) | 1989-01-10 | 1991-07-02 | Biosite Diagnostics, Inc. | Threshold ligand-receptor assay |
US5939272A (en) | 1989-01-10 | 1999-08-17 | Biosite Diagnostics Incorporated | Non-competitive threshold ligand-receptor assays |
US5922615A (en) | 1990-03-12 | 1999-07-13 | Biosite Diagnostics Incorporated | Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network |
WO1992005282A1 (en) | 1990-09-14 | 1992-04-02 | Biosite Diagnostics, Inc. | Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays |
US5955377A (en) | 1991-02-11 | 1999-09-21 | Biostar, Inc. | Methods and kits for the amplification of thin film based assays |
AU1911592A (en) | 1991-04-10 | 1992-11-17 | Biosite Diagnostics Incorporated | Novel conjugates and assays for simultaneous detection of multiple ligands |
ATE177841T1 (de) | 1991-04-10 | 1999-04-15 | Biosite Diagnostics Inc | ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung |
US6143576A (en) | 1992-05-21 | 2000-11-07 | Biosite Diagnostics, Inc. | Non-porous diagnostic devices for the controlled movement of reagents |
US6019944A (en) | 1992-05-21 | 2000-02-01 | Biosite Diagnostics, Inc. | Diagnostic devices and apparatus for the controlled movement of reagents without membranes |
US5494829A (en) | 1992-07-31 | 1996-02-27 | Biostar, Inc. | Devices and methods for detection of an analyte based upon light interference |
US5824799A (en) | 1993-09-24 | 1998-10-20 | Biosite Diagnostics Incorporated | Hybrid phthalocyanine derivatives and their uses |
US6498142B1 (en) * | 1996-05-06 | 2002-12-24 | Curis, Inc. | Morphogen treatment for chronic renal failure |
DK0907735T5 (da) * | 1996-05-24 | 2010-06-14 | Biogen Idec Inc | Modulatorer af vævsregenerering |
US5753455A (en) | 1996-09-03 | 1998-05-19 | Bayer Corporation | Method for the detection of lysozyme using a protein error indicator dye in conjunction with an alkane sulfonic acid |
US6113855A (en) | 1996-11-15 | 2000-09-05 | Biosite Diagnostics, Inc. | Devices comprising multiple capillarity inducing surfaces |
US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
US5773430A (en) | 1997-03-13 | 1998-06-30 | Research Foundation Of State University Of New York | Serine proteinase inhibitory activity by hydrophobic tetracycline |
US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
WO1998055508A2 (en) | 1997-06-03 | 1998-12-10 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS |
US20060223077A1 (en) * | 1997-06-06 | 2006-10-05 | Human Genome Sciences, Inc. | 207 human secreted proteins |
US6218122B1 (en) * | 1998-06-19 | 2001-04-17 | Rosetta Inpharmatics, Inc. | Methods of monitoring disease states and therapies using gene expression profiles |
US6958147B1 (en) * | 1998-10-26 | 2005-10-25 | Licentia Ltd | Use of VEGF-C to prevent restenosis |
BR9916407A (pt) * | 1998-12-21 | 2001-09-25 | Univ Monash | Detecção e tratamento de doenças dos rins |
RU2180965C1 (ru) | 2000-07-03 | 2002-03-27 | Габбасова Наталья Вадимовна | Способ дифференциальной диагностики заболеваний почек |
WO2002054081A2 (en) * | 2000-12-29 | 2002-07-11 | Oxford Glycosciences (Uk) Limited | Proteins, genes and their use for diagnosis and treatment of kidney response |
CA2442820A1 (en) * | 2001-03-29 | 2002-10-10 | Van Andel Institute | Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification |
US20070015146A1 (en) * | 2001-05-22 | 2007-01-18 | Gene Logic, Inc. | Molecular nephrotoxicology modeling |
US7235358B2 (en) * | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
US20030003588A1 (en) * | 2001-06-28 | 2003-01-02 | Comper Wayne D. | Method for kidney disease detection by protein profiling |
US7214373B2 (en) * | 2001-07-24 | 2007-05-08 | Yale University | Methods, compositions and kits relating to chitinases and chitinase-like molecules and inflammatory disease |
US6784154B2 (en) * | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
US8404229B2 (en) * | 2001-12-07 | 2013-03-26 | Cytori Therapeutics, Inc. | Methods of using adipose derived stem cells to treat acute tubular necrosis |
GB0130557D0 (en) | 2001-12-20 | 2002-02-06 | Serono Internat S A | Proteins |
CA2478288A1 (en) | 2002-03-07 | 2003-09-12 | Adrian Woolfson | Scd fingerprints |
WO2003081201A2 (en) * | 2002-03-21 | 2003-10-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Peripheral blood cell markers useful for diagnosing multiple sclerosis and methods and kits utilizing same |
US7138229B2 (en) * | 2002-12-06 | 2006-11-21 | Renovar, Inc. | Systems and methods for characterizing kidney diseases |
US7138230B2 (en) * | 2002-12-06 | 2006-11-21 | Renovar, Inc. | Systems and methods for characterizing kidney diseases |
AU2003281287A1 (en) | 2002-07-04 | 2004-01-23 | Oxford Glycosciences (Uk) Ltd | Toxicity markers |
US6941172B2 (en) * | 2002-11-18 | 2005-09-06 | Zvi Nachum | Method and device for restoring kidney function using electromagnetic stimulation |
WO2004053074A2 (en) * | 2002-12-06 | 2004-06-24 | Science And Technology Corporation @ Unm | Outcome prediction and risk classification in childhood leukemia |
CN1791797A (zh) | 2003-03-27 | 2006-06-21 | 儿童医院医疗中心 | 用于检测肾小管细胞损伤的早发的方法和试剂盒 |
KR20110094361A (ko) * | 2003-04-11 | 2011-08-23 | 메디뮨 엘엘씨 | 재조합 il9 항체 및 그의 용도 |
WO2005002416A2 (en) * | 2003-06-04 | 2005-01-13 | Joslin Diabetes Center, Inc. | Predictors of renal disease |
US20050148029A1 (en) * | 2003-09-29 | 2005-07-07 | Biosite, Inc. | Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes |
GB0329288D0 (en) * | 2003-12-18 | 2004-01-21 | Inverness Medical Switzerland | Monitoring method and apparatus |
US20070280930A1 (en) | 2004-03-17 | 2007-12-06 | Kasper Mathias Antoon Rouschop | Cd44-Targeting for Reducing/Preventing Ischemia-Reperfusion-Injury |
AU2005236075A1 (en) * | 2004-04-26 | 2005-11-03 | Children's Medical Center Corporation | Platelet biomarkers for the detection of disease |
US20050272101A1 (en) * | 2004-06-07 | 2005-12-08 | Prasad Devarajan | Method for the early detection of renal injury |
US7588892B2 (en) * | 2004-07-19 | 2009-09-15 | Entelos, Inc. | Reagent sets and gene signatures for renal tubule injury |
US20080038192A1 (en) * | 2004-07-19 | 2008-02-14 | Neurochem Inc. | Diagnostic Methods Of Multiple Organ Amyloidosis |
US7141382B1 (en) * | 2004-10-12 | 2006-11-28 | Parikh Chirag R | Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality |
PL1831699T3 (pl) | 2004-12-20 | 2010-04-30 | Antibodyshop As | Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek |
US20070092911A1 (en) | 2005-10-03 | 2007-04-26 | Buechler Kenneth F | Methods and compositions for diagnosis and /or prognosis in systemic inflammatory response syndromes |
WO2006083986A2 (en) | 2005-02-01 | 2006-08-10 | Government Of The U.S.A, As Represented By The Secretary Department Of Health & Human Services | Biomarkers for tissue status |
EP2604703B1 (en) * | 2005-03-14 | 2017-02-01 | The Board of Trustees of the Leland Stanford Junior University | Methods for evaluating graft survival in a solid organ transplant recipient |
US7608413B1 (en) * | 2005-03-25 | 2009-10-27 | Celera Corporation | Kidney disease targets and uses thereof |
US20070037232A1 (en) * | 2005-03-31 | 2007-02-15 | Barasch Jonathan M | Detection of NGAL in chronic renal disease |
AU2006238390B2 (en) * | 2005-04-18 | 2011-07-28 | Mitomics Inc. | Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers |
US20070087387A1 (en) * | 2005-04-21 | 2007-04-19 | Prasad Devarajan | Method for the Early Detection of Renal Disease Using Proteomics |
WO2007013919A2 (en) | 2005-07-21 | 2007-02-01 | The Johns Hopkins University | Methods of detecting and treating acute kidney injury |
EP1757940A1 (en) * | 2005-08-26 | 2007-02-28 | Cézanne S.A.S. | In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC |
US20080090304A1 (en) * | 2006-10-13 | 2008-04-17 | Barasch Jonathan Matthew | Diagnosis and monitoring of chronic renal disease using ngal |
US8329408B2 (en) * | 2005-10-31 | 2012-12-11 | Bayer Healthcare Llc | Methods for prognosis and monitoring cancer therapy |
US10716749B2 (en) * | 2005-11-03 | 2020-07-21 | Palo Alto Investors | Methods and compositions for treating a renal disease condition in a subject |
US20080133141A1 (en) * | 2005-12-22 | 2008-06-05 | Frost Stephen J | Weighted Scoring Methods and Use Thereof in Screening |
TW200726845A (en) * | 2006-01-02 | 2007-07-16 | Nat Defense Medical Ct | Biomarker molecular of renal illness and detecting method for the same |
GB0605217D0 (en) * | 2006-03-15 | 2006-04-26 | Novartis Ag | Method and compositions for assessing acute rejection |
GB0606776D0 (en) * | 2006-04-03 | 2006-05-10 | Novartis Pharma Ag | Predictive biomarkers for chronic allograft nephropathy |
US7662578B2 (en) * | 2006-04-21 | 2010-02-16 | Children's Hospital Medical Center | Method and kit for the early detection of impaired renal status |
US20080038269A1 (en) * | 2006-05-25 | 2008-02-14 | Mount Sinai Hospital | Methods for detecting and treating kidney disease |
WO2008084331A2 (en) | 2006-06-21 | 2008-07-17 | Hopitaux Universitaires De Geneve | Biomarkers for renal disorders |
US20090298073A1 (en) * | 2006-06-30 | 2009-12-03 | Gerhold David L | Kidney Toxicity Biomarkers |
WO2008009132A1 (en) * | 2006-07-21 | 2008-01-24 | The Governors Of The University Of Alberta | Tissue rejection |
GB0617429D0 (en) * | 2006-09-05 | 2006-10-18 | Electrophoretics Ltd | Markers of renal transplant rejection and renal damage |
US20080206794A1 (en) * | 2006-09-15 | 2008-08-28 | Renovar Incorporated | Systems And Methods For Characterizing Contrast Induced-Nephropathy |
EP2500723B1 (en) * | 2006-11-14 | 2015-07-08 | Alere San Diego, Inc. | Methods for monitoring and risk prediction in cardiorenal syndrome |
CA2665489C (en) * | 2006-12-08 | 2017-08-29 | The Children's Hospital Of Philadelphia | Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis |
GB0701626D0 (en) * | 2007-01-22 | 2007-03-07 | Cambridge Entpr Ltd | Methods and biomarkers for diagnosing and monitoring psychotic disorders |
WO2008104803A2 (en) | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
US8221995B2 (en) * | 2007-03-23 | 2012-07-17 | Seok-Won Lee | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
BRPI0809432A2 (pt) | 2007-03-26 | 2014-09-09 | Novartis Ag | Biomarcadores de segurança renal preditivos e assinaturas de biomarcadores para monitorar a função renal |
CA2682538A1 (en) | 2007-04-10 | 2008-10-16 | Integragen | Human diabetes susceptibility tnfrsf10b gene |
US8080394B2 (en) * | 2007-04-27 | 2011-12-20 | Brigham And Women's Hospital | Method for determining predisposition to pulmonary infection |
US9091695B2 (en) * | 2007-06-01 | 2015-07-28 | Laboratory Corporation Of America Holdings | Methods and systems for quantification of peptides and other analytes |
US20100184110A1 (en) | 2007-06-06 | 2010-07-22 | Siemens Healthcare Diagnostics Inc. | Predictive diagnostics for kidney disease |
US20090047689A1 (en) * | 2007-06-20 | 2009-02-19 | John Kolman | Autoantigen biomarkers for early diagnosis of lung adenocarcinoma |
US20100267041A1 (en) * | 2007-09-14 | 2010-10-21 | Predictive Biosciences, Inc. | Serial analysis of biomarkers for disease diagnosis |
WO2009038742A2 (en) | 2007-09-20 | 2009-03-26 | Caritas St. Elizabeth's Medical Center Of Boston, Inc. | Method for estimating risk of acute kidney injury |
WO2009039421A1 (en) * | 2007-09-20 | 2009-03-26 | University Of Louisville Research Foundation, Inc. | Peptide biomarkers predictive of renal function decline and kidney disease |
US8003333B2 (en) * | 2007-09-28 | 2011-08-23 | Mayo Foundation For Medical Education And Research | Serum biomarkers for early detection of acute cellular rejection |
US20110111427A1 (en) | 2008-02-29 | 2011-05-12 | Kenji Kadomatsu | Biomarker for the estimation of acute renal disorder and prognosis of the disorder, and use of the biomarker |
WO2009146450A2 (en) * | 2008-05-30 | 2009-12-03 | Therapeutic Monitoring Services, L.L.C. | Methods for monitoring immunosuppressant drug levels, renal function, and hepatic function using small volume samples |
US8241861B1 (en) * | 2008-07-08 | 2012-08-14 | Insilicos, Llc | Methods and compositions for diagnosis or prognosis of cardiovascular disease |
US7998744B2 (en) * | 2008-07-28 | 2011-08-16 | Greenwood Genetic Center, Inc. | Methods for determining dysregulation of methylation of brain expressed genes on the X chromosome to diagnose autism spectrum disorders |
US8673574B2 (en) * | 2008-08-21 | 2014-03-18 | Pxbiosciences Llc | Diagnosis and monitoring of renal failure using peptide biomarkers |
EP2743702B1 (en) | 2008-08-28 | 2017-08-09 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
CN105021826A (zh) | 2008-08-29 | 2015-11-04 | 阿斯图特医药公司 | 用于诊断和预后肾损伤和肾衰竭的方法和组合物 |
US8501489B2 (en) * | 2008-09-26 | 2013-08-06 | University of Pittsburgh—of the Commonwealth System of Higher Education | Urinary biomarkers to predict long-term dialysis |
EP3246707B1 (en) | 2008-10-21 | 2020-09-30 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
EP2347260A4 (en) * | 2008-10-21 | 2012-09-26 | Astute Medical Inc | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE |
EP2913676A1 (en) | 2008-11-10 | 2015-09-02 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
NZ601575A (en) | 2009-02-06 | 2014-08-29 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and failure |
US9229010B2 (en) * | 2009-02-06 | 2016-01-05 | Astute Medical, Inc. | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
US20120093811A1 (en) | 2009-04-03 | 2012-04-19 | Simmonds Jason W | Anti-vegf-d antibodies |
WO2010128158A1 (en) | 2009-05-08 | 2010-11-11 | Novartis Ag | Diagnostic biomarkers for fibrotic disorders |
WO2011017680A1 (en) * | 2009-08-07 | 2011-02-10 | Rules-Based Medicine,Inc | Computer methods and devices for detecting kidney damage |
NZ599105A (en) | 2009-09-21 | 2014-08-29 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
NZ600828A (en) | 2009-12-20 | 2014-09-26 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
US20130035290A1 (en) * | 2011-05-17 | 2013-02-07 | Yale University | Chitinase-3-Like Protein 1 as a Biomarker of Recovery from Kidney Injury |
-
2009
- 2009-08-28 EP EP14151433.1A patent/EP2743702B1/en active Active
- 2009-08-28 CN CN201510428254.8A patent/CN105067819B/zh not_active Expired - Fee Related
- 2009-08-28 MX MX2011002233A patent/MX2011002233A/es active IP Right Grant
- 2009-08-28 JP JP2011525260A patent/JP2012501456A/ja active Pending
- 2009-08-28 CA CA2735587A patent/CA2735587A1/en not_active Abandoned
- 2009-08-28 EP EP09810695.8A patent/EP2324355B1/en not_active Not-in-force
- 2009-08-28 CN CN200980140805.3A patent/CN102187220B/zh not_active Expired - Fee Related
- 2009-08-28 MX MX2013010617A patent/MX341926B/es unknown
- 2009-08-28 EP EP17185251.0A patent/EP3273246A1/en not_active Withdrawn
- 2009-08-28 AU AU2009285550A patent/AU2009285550B2/en not_active Ceased
- 2009-08-28 KR KR1020117006719A patent/KR20110073471A/ko not_active Application Discontinuation
- 2009-08-28 NZ NZ61035609A patent/NZ610356A/en not_active IP Right Cessation
- 2009-08-28 NZ NZ591437A patent/NZ591437A/xx not_active IP Right Cessation
- 2009-08-28 BR BRPI0917711A patent/BRPI0917711A2/pt not_active Application Discontinuation
- 2009-08-28 WO PCT/US2009/055449 patent/WO2010025424A1/en active Application Filing
- 2009-08-28 US US13/061,413 patent/US11150250B2/en active Active
-
2011
- 2011-07-12 HK HK11107251.6A patent/HK1153268A1/xx not_active IP Right Cessation
-
2014
- 2014-11-25 HK HK14111890A patent/HK1198391A1/xx not_active IP Right Cessation
-
2015
- 2015-10-22 JP JP2015208192A patent/JP6126186B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-02 HK HK16101184.6A patent/HK1213320A1/zh not_active IP Right Cessation
-
2021
- 2021-09-13 US US17/473,710 patent/US20230020055A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4339405B2 (ja) * | 1996-10-31 | 2009-10-07 | 持田製薬株式会社 | 予防・治療剤 |
JP2005534641A (ja) * | 2002-05-23 | 2005-11-17 | トラスティース・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア | Fasペプチド模倣体およびその使用 |
WO2005042719A2 (en) * | 2003-10-30 | 2005-05-12 | The Cbr Institute For Biomedical Research, Inc. | Methods for treating and preventing ischemia-reperfusion injury using rna interfering agents |
US20070031905A1 (en) * | 2005-08-02 | 2007-02-08 | Board Of Regents, The University Of Texas System | Soluble fas urinary marker for the detection of bladder transitional cell carcinoma |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110221337A (zh) * | 2019-06-28 | 2019-09-10 | 南华大学 | 一种利用α-1抗蛋白酶评价铀矿粉尘内照射生物损伤的方法 |
CN110221337B (zh) * | 2019-06-28 | 2022-07-01 | 南华大学 | 一种利用α-1抗蛋白酶评价铀矿粉尘内照射生物损伤的方法 |
Also Published As
Publication number | Publication date |
---|---|
KR20110073471A (ko) | 2011-06-29 |
AU2009285550A1 (en) | 2010-03-04 |
CN102187220A (zh) | 2011-09-14 |
CA2735587A1 (en) | 2010-03-04 |
MX2011002233A (es) | 2011-09-27 |
HK1213320A1 (zh) | 2016-06-30 |
US11150250B2 (en) | 2021-10-19 |
EP2324355A4 (en) | 2011-11-23 |
CN105067819A (zh) | 2015-11-18 |
AU2009285550B2 (en) | 2015-06-18 |
CN105067819B (zh) | 2018-05-22 |
EP2743702A2 (en) | 2014-06-18 |
EP2743702B1 (en) | 2017-08-09 |
US20110195429A1 (en) | 2011-08-11 |
WO2010025424A1 (en) | 2010-03-04 |
MX341926B (es) | 2016-09-07 |
EP2743702A3 (en) | 2014-09-17 |
EP2324355A1 (en) | 2011-05-25 |
HK1153268A1 (en) | 2012-03-23 |
EP3273246A1 (en) | 2018-01-24 |
JP2012501456A (ja) | 2012-01-19 |
HK1198391A1 (en) | 2015-04-17 |
NZ591437A (en) | 2013-07-26 |
BRPI0917711A2 (pt) | 2017-06-20 |
EP2324355B1 (en) | 2014-01-22 |
JP6126186B2 (ja) | 2017-05-10 |
CN102187220B (zh) | 2015-08-19 |
US20230020055A1 (en) | 2023-01-19 |
NZ610356A (en) | 2015-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6580227B2 (ja) | 腎損傷および腎不全の診断および予後のための方法および組成物 | |
JP6126186B2 (ja) | 腎損傷および腎不全の診断および予後のための方法および組成物 | |
JP5947544B2 (ja) | 腎損傷および腎不全の診断および予後のための方法および組成物 | |
JP5955879B2 (ja) | 腎損傷および腎不全の診断および予後のための方法および組成物 | |
JP5752600B2 (ja) | 腎損傷および腎不全の診断および予後のための方法 | |
JP5735922B2 (ja) | 腎損傷および腎不全の診断および予後のための方法 | |
JP5775874B2 (ja) | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 | |
JP2017032586A (ja) | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 | |
JP7217796B2 (ja) | 腎障害および腎不全の診断および予後のための方法および組成物 | |
JP5827226B2 (ja) | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 | |
JP5981144B2 (ja) | 腎損傷および腎不全の診断および予後診断 | |
JP6403712B2 (ja) | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 | |
JP2016029379A (ja) | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 | |
JP2017534874A (ja) | 腎損傷および腎不全の診断および予後のための方法および組成物。 | |
JP2015508181A (ja) | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 | |
AU2015202151A1 (en) | Methods and compositions for diagnosis and prognosis of renal injury and renal failure | |
JP2016505860A (ja) | 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160808 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160816 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161114 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170328 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170406 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6126186 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |